Explore

Trendline Trendline
Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress

Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress

Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress
Trendline Trendline
Gilead Sciences Announces $3 Billion Senior Unsecured Notes Offering for Corporate Expansion

Gilead Sciences Announces $3 Billion Senior Unsecured Notes Offering for Corporate Expansion

Gilead Sciences Announces $3 Billion Senior Unsecured Notes Offering for Corporate Expansion
Trendline Trendline
Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses
Trendline Trendline
Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026
Trendline Trendline
Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates

Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates

Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates
Trendline Trendline
MacroGenics Extends Cash Runway to 2028 Through Asset Monetization and Manufacturing Divestiture

MacroGenics Extends Cash Runway to 2028 Through Asset Monetization and Manufacturing Divestiture

MacroGenics Extends Cash Runway to 2028 Through Asset Monetization and Manufacturing Divestiture
Trendline Trendline
Bora Acquires MacroGenics Facility for $122.5M to Expand U.S. Presence

Bora Acquires MacroGenics Facility for $122.5M to Expand U.S. Presence

Bora Acquires MacroGenics Facility for $122.5M to Expand U.S. Presence
Trendline Trendline
Immunome Advances Cancer Therapy Pipeline with New Drug Application and Clinical Trials

Immunome Advances Cancer Therapy Pipeline with New Drug Application and Clinical Trials

Immunome Advances Cancer Therapy Pipeline with New Drug Application and Clinical Trials
Trendline Trendline
Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy

Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy

Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy
Trendline Trendline
Palatin Technologies Reports Q3 2026 Financial Results and Business Progress

Palatin Technologies Reports Q3 2026 Financial Results and Business Progress

Palatin Technologies Reports Q3 2026 Financial Results and Business Progress
Trendline Trendline
Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development

Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development

Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development
Trendline Trendline
Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026

Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026

Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026